ISIN | LU0942225912 |
---|---|
Valor Number | 21612660 |
Bloomberg Global ID | |
Fund Name | Candriam Equities L Biotechnology R-Acc |
Fund Provider |
CANDRIAM
Serenity, Bloc - B, 19-21, route d'Arlon 8009 Strassen E-Mail: CH@Candriam.com Phone: + 352 2797-1 Web: https://www.candriam.com |
Fund Provider | CANDRIAM |
Representative in Switzerland |
CACEIS Bank, Montrouge, Zurich Branch / Switzerland Zurich Phone: +41 44 405 97 00 |
Distributor(s) | |
Asset Class | Equities |
EFC Category | |
Distribution Policy | Accumulation |
Home Country | Luxembourg |
Issuing Condition | Combination of issuing commission charged by the fund management company and transaction fee charged by the fund |
Redemption Condition | Combination of redemption commission charged by the fund management company and transaction fee charged by the fund |
Investment Strategy *** | The objective of the sub-fund is to use discretionary management to benefit from the performance of the market in global equities of companies from the biotechnology sector, and to outperform the benchmark. This sub-fund may be appropriate for investors who wish to achieve this objective over a long investment holding period and who are aware of, understand and are able to bear the specific risks of the sub-fund. |
Peculiarities |
Current Price * | 282.17 USD | 17.12.2024 |
---|---|---|
Previous Price * | 280.01 USD | 16.12.2024 |
52 Week High * | 307.14 USD | 08.11.2024 |
52 Week Low * | 246.59 USD | 20.12.2023 |
NAV * | 282.17 USD | 17.12.2024 |
Issue Price * | ||
Redemption Price * | ||
Closing Price * | ||
Indicative Minimum Price | ||
Fund Assets *** | 1,485,049,431 | |
Unit/Share Assets *** | 35,298,614 | |
Trading Information SIX |
YTD Performance | +7.77% |
29.12.2023 - 17.12.2024
29.12.2023 17.12.2024 |
---|---|---|
YTD Performance (in CHF) | +14.32% |
29.12.2023 - 17.12.2024
29.12.2023 17.12.2024 |
1 month | +3.31% |
18.11.2024 - 17.12.2024
18.11.2024 17.12.2024 |
3 months | -5.97% |
17.09.2024 - 17.12.2024
17.09.2024 17.12.2024 |
6 months | +4.87% |
17.06.2024 - 17.12.2024
17.06.2024 17.12.2024 |
1 year | +13.23% |
18.12.2023 - 17.12.2024
18.12.2023 17.12.2024 |
2 years | +17.88% |
19.12.2022 - 17.12.2024
19.12.2022 17.12.2024 |
3 years | +15.31% |
17.12.2021 - 17.12.2024
17.12.2021 17.12.2024 |
5 years | +36.72% |
17.12.2019 - 17.12.2024
17.12.2019 17.12.2024 |
Equity Participation Rate in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Share of Total Fund Assets in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Real Estate Rate in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ADDI | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ADDI Date |
Amgen Inc | 6.09% | |
---|---|---|
Gilead Sciences Inc | 5.63% | |
Regeneron Pharmaceuticals Inc | 5.26% | |
Vertex Pharmaceuticals Inc | 5.07% | |
Alnylam Pharmaceuticals Inc | 4.78% | |
BioNTech SE ADR | 3.26% | |
Eli Lilly and Co | 2.59% | |
argenx SE | 2.27% | |
Neurocrine Biosciences Inc | 2.13% | |
Insmed Inc | 1.96% | |
Last data update | 31.10.2024 |
TER *** | 1.11% |
---|---|
TER date *** | 30.06.2024 |
Performance Fee *** | |
PTR | |
Max. Management Fee *** | 0.90% |
Ongoing Charges *** | 1.10% |
SRRI ***
|
|
SRRI date *** | 30.11.2024 |
Low Carbon Designation *** | |
---|---|
ESG Rating Overall *** | |
ESG Rating Corporate *** | |
ESG Rating Sovereign *** | |
% AuM H&S Controversies *** |
Avg Carbon Risk Score *** | |
---|---|
Avg Carbon Risk Cat Avg *** | |
% AuM Covered Carbon *** | |
Avg Fossil Fuel Exposure *** | |
Fossil Fuel Cat Avg *** |
Strategy Level 1 *** | |
---|---|
Strategy Level 2 *** | |
Strategy Level 3 *** | |
Exclusions Level 1 *** | |
Exclusions Level 2 *** |